Efficacy of Sulphadoxine-pyrimethamine and Artemisinin-containing Combination Therapy for Malaria
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
This is an ongoing monitoring activity of efficacy of sulfadoxine-pyrimethamine (SP), which
is the current national treatment of choice for uncomplicated malaria in Tanzania, and a
combination of SP and artesunate among children < 5 years in 3 sites in rural Tanzania.
Protocol was amended in 2004 to (1) include lumefantrine+artemether, the newly identified
first-line treatment for malaria to be introduced into Tanzania in 2006; (2) on a limited
basis, include adult patients; (3) extend follow-up to 28 days; (4) investigate whether
treated bednets would reduce confounding by reinfection
Phase:
Phase 4
Details
Lead Sponsor:
Centers for Disease Control and Prevention
Collaborator:
United States Agency for International Development (USAID)
Treatments:
Artemether Artesunate Fanasil, pyrimethamine drug combination Lumefantrine Pyrimethamine Sulfadoxine